Drug Profile
Research programme: GITR antibodies - Five Prime Therapeutics/Inhibrx
Alternative Names: FPA-154; INBRX-110Latest Information Update: 21 Apr 2021
Price :
$50
*
At a glance
- Originator Inhibrx
- Class Antibodies
- Mechanism of Action Immunostimulants; TNFRSF18 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer